NBIX vs. GRDN: Which Stock Is the Better Value Option?

Zacks
Открыть на Zacks
NBIX vs. GRDN: Which Stock Is the Better Value Option?

Investors looking for stocks in the Medical - Drugs sector might want to consider either Neurocrine Biosciences (NBIX) or Guardian Pharmacy Services (GRDN). But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer look.

Everyone has their own methods for finding great value opportunities, but our model includes pairing an impressive grade in the Value category of our Style Scores system with a strong Zacks Rank. The proven Zacks Rank puts an emphasis on earnings estimates and estimate revisions, while our Style Scores work to identify stocks with specific traits.

Right now, Neurocrine Biosciences is sporting a Zacks Rank of #2 (Buy), while Guardian Pharmacy Services has a Zacks Rank of #3 (Hold). This system places an emphasis on companies that have seen positive earnings estimate revisions, so investors should feel comfortable knowing that NBIX is likely seeing its earnings outlook improve to a greater extent. But this is only part of the picture for value investors.

Value investors are also interested in a number of tried-and-true valuation metrics that help show when a company is undervalued at its current share price levels.

Our Value category grades stocks based on a number of key metrics, including the tried-and-true P/E ratio, the P/S ratio, earnings yield, and cash flow per share, as well as a variety of other fundamentals that value investors frequently use.

NBIX currently has a forward P/E ratio of 16.05, while GRDN has a forward P/E of 32.48. We also note that NBIX has a PEG ratio of 0.55. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. GRDN currently has a PEG ratio of 2.00.

Another notable valuation metric for NBIX is its P/B ratio of 4.3. The P/B ratio pits a stock's market value against its book value, which is defined as total assets minus total liabilities. For comparison, GRDN has a P/B of 7.55.

Based on these metrics and many more, NBIX holds a Value grade of B, while GRDN has a Value grade of C.

NBIX stands above GRDN thanks to its solid earnings outlook, and based on these valuation figures, we also feel that NBIX is the superior value option right now.

Zacks' Research Chief Names "Stock Most Likely to Double"

Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.

This innovative software-as-a-service firm upped its user base +22% year over year. That rate is increasing and margins are expanding as AI efficiencies take effect. Of course, all our elite picks aren't winners, but this one could far surpass earlier Zacks' Stocks Set to Double like D-Wave Quantum, which shot up +680.1%.

Free: See Our Top Stock And 4 Runners Up

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report


 
Neurocrine Biosciences, Inc. (NBIX): Free Stock Analysis Report
 
Guardian Pharmacy Services, Inc. (GRDN): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research